Compared to
the current share price of EUR 17.89, this fair value price target now offers an Upside Potential of 168 %.
An appropriate strike price is just below
the current share price of the stock.
Example - If
the current share price of a company is $ 50 and an annualized dividend of $ 1, then its yield would be 2 %.
While I'm not convinced that the full $ 4.50 per share will ever be realized by shareholders, I think that
the current share price of $ 2.45 still discounts the company's assets too steeply.
So with limited potential upside and significant downside (if the remerging of the entities can not be achieved), I will be holding my position and possibly even pruning it if Mr. Market becomes exuberant, rather than increasing my exposure, even though, at
the current share price of $ 3.07, there is a 16 % upside to the implied liquidation value.
At
the current share price of $ 9.00 Exelis now trades at just under 5x projected 2011 earnings, considerably below the P / Es of the other defense companies in the table above.
Not bad at
the current share price of about $ 35.
A $ 0.20 per share dividend trading on a 7 % yield equates to $ 2.86, well above
the current share price of $ 1.90.
For investors looking to buy TD shares now, the dividend yield they can expect based on
the current share price of just under $ 75 comes out to ~ 3.6 %.
If we divide that by the number of shares outstanding (1,682,167), that equates to a TBV of $ 26.73 compared to the company's
current share price of $ 20.15.
Using our binoculars, Wall Street's expected $ 0.43 in EPS by 2019 looks particularly attractive next to Yamana's
current share price of just $ 3.02.
At Valuentum, we often use a discounted cash - flow model as a means to back into
the current share price of firms in order to ascertain whether the market is unfairly pricing their stock relative to reasonable long - term growth and profitability assumptions.
Pachter has consistently been one of the most bearish analysts on Wall Street, rating the company underperform with a $ 40 price target, compared to
a current share price of around $ 100.
Gerstner said he thinks United Airlines stock is worth double or triple
its current share price of about $ 75, or even more, with his target price at as much as $ 235 a share.
Normally, an ETF's share price equals the weighted average of
the current share prices of all the individual stocks the ETF owns.
Not exact matches
T. Rowe dropped Dropbox
shares by 16 percent, meaning the
current value
of its holdings in that company is reportedly under water — 13 percent below the firm's original purchase
price in 2012.
The Instagram story also shows that she was given 995 Adidas (addyy)
shares, which would also have a total value
of around $ 100,000 at
current prices.
The lot size rule for Japan
shares makes it hard for Nintendo to widen the base
of investors at the
current price, says Atul Goyal
of Jefferies.
Corey Davis, an analyst with investment firm Jefferies & Co., estimates
shares will rise to $ 1.44 in 2014 (about a 60 cents jump from the
current price) after the combined company has a full year
of operations under its belt.
Similarly, the volume simply converted based on the
current share price is expected to reach a total
of 2.37 million
shares consisting
of the existing 1.61 million ordinary
shares (2.04 million before division) and 0.76 million
shares to be additionally purchased and retired.
For instance, a company may give an employee the right to buy 100
shares at the
current price of $ 10 per
share in 1998.
HelloFresh sold 31 million new
shares in an initial public offering, giving it a valuation around 1.7 billion euros at
current prices — more than double the $ 888 million (763 million euro) market capitalization
of struggling Blue Apron (aprn).
The stock has been a Wall Street whirlwind since its late January 2015 IPO, initially surging more than 100 percent to $ 96.75 a
share, only to fall nearly 50 percent to its
current price of around $ 49.
Still, Fitbit has something
of a first - mover advantage that's likely to keep its
share price floating at its
current level
of around $ 32, which is more than 40 percent higher than its trading start
price.
Wells Fargo downgraded the company to market underperform, and put a
price target
of $ 7 a
share on it, over a buck above its
current price — always lagging behind, always keeping that optimism going.
Microsoft's
share price is also a good arbiter
of that decision to stay the course in PCs, and an inability to get
current.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market
share and
price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering
prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and
current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its
share repurchase program due to changes in its stock
price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
To calculate a company's market capitalization, multiply its
current share price by its number
of outstanding
shares.
Examples
of such projects providing marginal benefits are: improving financial reporting systems through better information technology, minor tweaks to supply chain logistics, cutting back on marketing or increasing low - cost advertising (like social media), «rationalization»
of head count, holding average wages as low as possible, squeezing suppliers a little bit, not repatriating earnings to stave off taxation, refinancing rather than retiring debts, and the
share buyback that is insensitive to a company's
current stock
price.
The second rule
of thumb relates to our
current fuel derivative portfolio where a 10 % reduction in the
price of Brent for the remaining half
of 2012 would result in an additional $ 0.04
of realized losses on fuel derivatives that would offset the $ 0.13 per
share favorable impact from the reduced
price of fuel.
Using our
current fuel
price of $ 620 per metric ton, we are currently estimating that lower fuel
prices should benefit first half 2013 earnings per
share by approximately $ 0.23.
With virtually identical market capitalization (the
price it would take to buy all
shares of a company's outstanding common stock at the
current market value), what exactly is an investor in each respective firm getting for his or her money?
The company in August sold 1.5 million unregistered
shares to a private investor who is also a
current shareholder at a
price of $ 2.10 per
share, for aggregate consideration
of $ 3.15 million.
At its
current price of $ 55 /
share, HLF has a
price to economic book value (PEBV) ratio
of 1.4.
At its
current valuation
of ~ $ 67 /
share, HLF has a
price to economic book value ratio (
price - to - EBV)
of 1.2 That ratio means that the market expects only 20 % growth in NOPAT for the remainder
of HLF's existence.
Moreover, as home
prices rose, household net worth increased, making households more willing to consume a greater
share of their
current income.
THL Credit pays quarterly dividends
of $ 0.27 per
share, giving TCRD stock a staggering annual yield
of 13.8 % at the
current price.
In order to justify its
current price of $ 31 /
share, the company would need to grow NOPAT by 15 % compounded annually for the next 5 years.
To justify the
current price of $ 47 /
share, Jarden must grow NOPAT by 13 % compounded annually for the next 16 years, at which point, Jarden would be generating over $ 66 billion in revenue.
The billionaire investor, 79, held 1.41 million Netflix
shares as
of March 31, according to data compiled by Bloomberg, making the latest sales worth about $ 960 million at
current prices.
This ratio is calculated by dividing the
current Price by the sum
of the Basic Earnings Per
Share from continuing operations BEFORE Extraordinary Items and Accounting Changes over the last four quarters.
At its
current price of $ 105 /
share, HAS has a
price - to - economic book value (PEBV) ratio
of 1.2.
Price - to - Earnings (P / E) Ratio The ratio of a company's current share price to its reported earn
Price - to - Earnings (P / E) Ratio The ratio
of a company's
current share price to its reported earn
price to its reported earnings.
At its
current price of $ 142 /
share, CLX has a
price - to - economic book value (PEBV) ratio
of 1.2.
The ratio
of a company's
current share price to reported sales.
The
current value
of shares is determined by multiplying the number
of shares by their highest
current public offering
price.
Through these schemes, Shkreli obtained over $ 5.6 million in cash and Retrophin
shares or the use
of Retrophin
shares worth over $ 59 million (at
current market
prices).
One important metric used is the
price - to - earnings ratio, or, the
current price of the stock divided by the average earnings per
share (yearly revenue divided by the number
of outstanding
shares).
Despite the impressive fundamentals, at its
current price of $ 66 /
share, Wal - Mart has a PEBV ratio
of 0.8.
As a result
of these agreements, Retrophin paid $ 200,000 in cash and issued 581,000
shares to MSMB investors, resulting in a benefit to Shkreli
of over $ 17.3 million (at
current market
prices), and is embroiled in an arbitration with Rosenfeld in which Rosenfeld is seeking $ 1,650,000.